N/A:ORGS
Orgenesis Inc.
A pre-revenue biotech firm developing cell therapy solutions for cancer treatment, currently facing severe liquidity constraints and massive annualized losses.
Key Metrics
Investment Thesis
Bull Case
An investor might consider ORGS if they believe the company has secured undisclosed major funding rounds that are not yet reflected in current filings, potentially turning the tide on its liquidity issues. The company holds significant intangible assets and R&D investments ($10.6M) that could yield high-value breakthroughs if clinical trials succeed in the oncology market. A successful partnership announcement could instantly revalue the company's $7.4M in operating net intangible assets, offering a massive potential return on investment for early-stage holders.
Bear Case
The stock presents an extreme downside risk given the collapse in revenue to near-zero levels and a retained earnings deficit of -$176.6M that threatens permanent capital destruction. With total liabilities exceeding $35M against only $1.5M in cash, the firm is likely facing imminent delisting or bankruptcy rather than a path to profitability. The massive operating expenses ($47.9M) with no corresponding revenue growth indicate management has failed to pivot to a viable commercial model.
About Orgenesis Inc.
Orgenesis Inc. (ORGS) operates within the biotechnology sector, focusing on developing cell therapy technologies and therapeutic products primarily for oncology markets. The company's recent financial profile indicates a deep capital-intensive R&D environment with significant operating losses and minimal current revenue generation. Key strategic efforts are directed toward advancing clinical candidates to achieve commercialization milestones in specialized healthcare verticals.
Analysis
Management Discussion
The company's financial performance has deteriorated sharply, evidenced by a precipitous drop in revenue from $36M to $0.5M and a net loss widening to -$64.9M in the most recent year. Cash flow from operations turned negative at -$14.8M while ending cash reserves plummeted from $6.4M to just $1.5M, signaling a critical liquidity crunch. Despite massive non-cash adjustments of $73M and financing inflows, the structural inability to generate profit or revenue suggests the current business model is untenable without a radical pivot or successful external capital injection.
Industry Overview
The biotechnology and cell therapy industry is characterized by high failure rates, long development cycles, and heavy reliance on external financing before commercialization. Companies in this space often experience volatile revenue profiles as they transition from research phases to clinical trials and eventual product launch. Success requires substantial capital reserves to sustain R&D burn until a therapeutic achieves FDA approval and market adoption.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 |
|---|---|---|
| Revenue | $36.0M | $530.0K |
| Cost of Revenue | $27.1M | $6.3M |
| Gross Profit | $9.0M | $-5.7M |
| Operating Expenses | $17.6M | $47.9M |
| Operating Income | $-8.6M | $-53.6M |
| R&D | — | $10.6M |
| G&A | $15.6M | $35.1M |
| Stock-Based Comp | $982.0K | $463.0K |
| D&A | $2.0M | $1.6M |
| Depreciation | $1.1M | $839.0K |
| Amortization | $911.0K | $721.0K |
| Other OpEx | $2.0M | $2.2M |
| Non-Operating Income | $-3.4M | $-10.8M |
| Pre-Tax Income | $-12.0M | $-64.4M |
| Income Tax | $209.0K | $473.0K |
| Continuing Ops | $-12.2M | $-64.9M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-12.2M | $-64.9M |
| Minority Interest | $2.7M | $-9.6M |
| Net to Common | $-14.9M | $-55.4M |
| Metric | 2022 | 2023 |
|---|---|---|
| Current Assets | $46.3M | $4.1M |
| Cash & Equivalents | $5.3M | $837.0K |
| Accounts Receivable | $36.2M | $88.0K |
| Inventory | $120.0K | $34.0K |
| Prepaid Expenses | $958.0K | $2.0M |
| Other Current Assets | $3.7M | $1.1M |
| Long-Term Assets | $44.6M | $10.5M |
| PP&E (Net) | $22.8M | $1.5M |
| Intangibles | $9.7M | $7.4M |
| Goodwill | $8.2M | $1.2M |
| Operating Leases | $2.3M | $351.0K |
| LT Investments | $135.0K | $8.0K |
| Other LT Assets | $1.3M | $48.0K |
| Total Assets | $90.9M | $14.6M |
| Current Liabilities | $15.9M | $16.4M |
| Accounts Payable | $4.4M | — |
| Current Leases | $542.0K | $216.0K |
| Deferred Revenue | $70.0K | $200.0K |
| Taxes Payable | $289.0K | $740.0K |
| Other Current Liab | $8.0M | $13.0M |
| Long-Term Liabilities | $15.7M | $19.1M |
| LT Operating Leases | $1.7M | $96.0K |
| Other LT Liab | $14.0M | $19.0M |
| Total Liabilities | $31.7M | $35.5M |
| Shareholders' Equity | $59.3M | $-21.0M |
| Retained Earnings | $-121.3M | $-176.6M |
| AOCI | $-270.0K | $65.0K |
| Treasury Stock | $1.3M | $1.3M |
| Total L&E | $90.9M | $14.6M |
| Metric | 2022 | 2023 |
|---|---|---|
| Net Income (CFO) | $-12.2M | $-64.9M |
| Non-Cash Adjustments | $-33.5M | $73.0M |
| Working Capital Changes | $20.8M | $-22.9M |
| Cash from Operations | $-24.9M | $-14.8M |
| Capital Expenditures | $12.4M | $2.1M |
| Cash from Investing | $-14.1M | $-3.7M |
| Cash from Financing | $39.6M | $13.6M |
| FX Effect | $-126.0K | $36.0K |
| Net Change in Cash | $521.0K | $-4.9M |
| Beginning Cash | $6.0M | $6.4M |
| Ending Cash | $6.4M | $1.5M |
Frequently Asked Questions
How does Orgenesis Inc. make money?
1) Cell Therapy Development: The primary revenue stream involves research and development expenses of $10.6M focused on oncology candidates, with no commercial sales recorded in the latest period. 2) Licensing and Collaboration: Although not explicitly detailed as a separate revenue line, the company relies heavily on external financing ($13.6M cash flow from financing) to offset operational deficits, suggesting potential reliance on milestone payments or strategic partnerships typical for this stage of biotech. 3) Intellectual Property Monetization: The portfolio includes intangible assets valued at $7.4M and goodwill of $1.2M, representing the core value drivers awaiting commercial validation.
What are the main risks for ORGS?
1) Severe Liquidity Crisis: The company operates with only $1.5M in ending cash against $64.9M in net losses and $35.5M in total liabilities, creating an imminent risk of insolvency without immediate fundraising. 2) Commercialization Uncertainty: With revenues dropping from $36M to $0.5M in a single year, the business model faces extreme volatility and a high probability of failing to generate sustainable cash flow. 3) High Burn Rate: Operating expenses surged to $47.9M while revenue collapsed, indicating an unsustainable burn rate that cannot be supported by current financial resources.
What is ORGS's competitive advantage?
1) Proprietary Platform Technology: Orgenesis likely leverages unique cell engineering capabilities that differentiate its product pipeline from competitors in the crowded oncology space. 2) Specialized Clinical Expertise: The company possesses deep institutional knowledge in navigating complex regulatory pathways for novel cell therapies, a critical moat before commercial launch. 3) Strategic Partnership Potential: With significant other shareholders equity and external financing history, the firm is positioned to attract major pharma partners once clinical data proves efficacy.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.